Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MK-8591B-060 | Other Identifier | MSD |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Investigators are trying to find better treatments for people with HIV-1. In this clinical study, investigators want to see how well a new treatment called ISL+ULO, taken once a week, works compared to an existing treatment called BIC/FTC/TAF, which is taken every day. Investigators will check how many people still have a high level of the virus in their blood after 24 weeks. The investigators also want to understand if the new treatment, MK-8591B, is safe and how well people can handle it.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ISL + ULO in Group 1 | Experimental | In part 1 of the study, participants will receive ISL 2mg + ULO 200mg orally once a week (QW) for 48 weeks. In part 2 (2nd 48 weeks), participants will continue to receive ISL 2mg + ULO 200mg once a week till week 96. |
|
| BIC/FTC/TAF in Group 2 | Active Comparator | In part 1 of the study, participants will receive BIC 50mg/FTC 200mg/TAF 25mg orally once daily (QD) for 48 weeks. |
|
| ISL + ULO in Group 2 | Experimental | In part 2 of the study, participants previously on BIC/FTC/TAF (for the 1st 48 weeks, or part 1) will switch to ISL + ULO, to week 96. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ISL | Drug | ISL 1mg oral capsule will be administered as 2mg orally (each capsule 1mg) as part of ISL and ULO combination to group 1 participants for 96 weeks and for group 2 participants in part 2 of the study from 49 to 96 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With HIV-1 RNA ≥50 copies/mL at Week 24 | Plasma HIV-1 ribonucleic acid (RNA) quantification will be performed at the central laboratory using a polymerase chain reaction (PCR) assay. Percentage of participants with HIV-1 RNA ≥50 copies/mL will be reported at week 24. | Week 24 |
| Percentage of Participants who Experience an Adverse Event (AE) | An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The percentage of participants who experience an AE will be reported. | Up to ~ 96 weeks |
| Percentage of Participants Discontinuing Study Treatment due to AEs | An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The percentage of participants who discontinue study treatment due to an AE will be reported. | Up to ~ 96 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With HIV-1 RNA ≥50 copies/mL at Week 48 | Plasma HIV-1 RNA quantification will be performed at the central laboratory using a polymerase chain reaction (PCR) assay. Percentage of participants with HIV-1 RNA ≥50 copies/mL will be reported at week 48. | Week 48 |
| Percentage of Participants With HIV-1 RNA <50 copies/mL at Week 24 |
Not provided
Inclusion:
The main inclusion criteria include but are not limited to the following:
- Has been receiving Bictegravir/Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF) therapy with documented viral suppression [Human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) <50 copies/mL] for ≥6 months prior to providing documented informed consent and has no history of prior virologic treatment failure on any past or current regimen.
Exclusion:
The main exclusion criteria include but are not limited to the following:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Merck Sharp & Dohme LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Zuckerberg San Francisco General Hospital and Trauma Center ( Site 4107) | San Francisco | California | 94110 | United States | ||
Not provided
| Label | URL |
|---|---|
| Merck Clinical Trials Information | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| ULO | Drug | ULO 100mg oral tablet will be administered as 200mg (2 tablets) orally as part of ISL and ULO combination to group 1 participants for 96 weeks and for group 2 participants in part 2 of the study from 49 to 96 weeks. |
|
|
| BIC/FTC/TAF | Drug | BIC 50mg oral tablet/FTC 200mg oral tablet/TAF 25 mg oral tablet administered orally to group 2 participants for 48 weeks in part 1 of the study. |
|
|
Plasma HIV-1 RNA quantification will be performed at the central laboratory using a PCR assay. Percentage of participants with HIV-1 RNA <50 copies/mL will be reported at week 24. |
| Week 24 |
| Percentage of Participants With HIV-1 RNA <50 copies/mL at Week 48 | Plasma HIV-1 RNA quantification will be performed at the central laboratory using a PCR assay. Percentage of participants with HIV-1 RNA <50 copies/mL will be reported at week 48. | Week 48 |
| Percentage of Participants With HIV-1 RNA <200 copies/mL at Week 24 | Plasma HIV-1 RNA quantification will be performed at the central laboratory using a PCR assay. Percentage of participants with HIV-1 RNA <200 copies/mL will be reported at week 24. | Week 24 |
| Percentage of Participants With HIV-1 RNA <200 copies/mL at Week 48 | Plasma HIV-1 RNA quantification will be performed at the central laboratory using a PCR assay. Percentage of participants with HIV-1 RNA <200 copies/mL will be reported at week 48. | Week 48 |
| Percentage of Participants With HIV-1 RNA ≥50 copies/mL at Week 96 | Plasma HIV-1 RNA quantification will be performed at the central laboratory using a PCR assay. Percentage of participants with HIV-1 RNA ≥50 copies/mL will be reported at week 96. | Week 96 |
| Percentage of Participants With HIV-1 RNA <50 copies/mL at Week 96 | Plasma HIV-1 RNA quantification will be performed at the central laboratory using a PCR assay. Percentage of participants with HIV-1 RNA <50 copies/mL will be reported at week 96. | Week 96 |
| Percentage of Participants With HIV-1 RNA <200 copies/mL at Week 96 | Plasma HIV-1 RNA quantification will be performed at the central laboratory using a PCR assay. Percentage of participants with HIV-1 RNA <200 copies/mL will be reported at week 96. | Week 96 |
| Mean Change From Baseline in CD4+ T-cell Count at Week 24 | The mean change from baseline in CD4+ T-cell count will be calculated at each applicable time point at which CD4+ T-cell count is collected with primary interest at 24 weeks. Blood samples are taken for this purpose. Baseline measurements are defined as the Day 1 value for each participant. | Week 24 |
| Mean Change From Baseline in CD4+ T-cell Count at Week 48 | The mean change from baseline in CD4+ T-cell count will be calculated at each applicable time point at which CD4+ T-cell count is collected with primary interest at 48 weeks. Blood samples are taken for this purpose. Baseline measurements are defined as the Day 1 value for each participant. | Week 48 |
| Mean Change From Baseline in CD4+ T-cell Count at Week 96 | The mean change from baseline in CD4+ T-cell count will be calculated at each applicable time point at which CD4+ T-cell count is collected with primary interest at 96 weeks. Blood samples are taken for this purpose. Baseline measurements are defined as the Day 1 value for each participant. | Week 96 |
| Percentage of Participants With Development of Viral Drug Resistance to any Component of Study Intervention at Week 24 | Antiviral drug resistance is the reduced susceptibility of the virus to the study intervention. Participants with HIV-1 RNA ≥400 copies/mL will be included in the resistance analyses. Participants who have test results showing signs of viral resistance will also be included for analysis, irrespective of the viral load. Percentage of participants in each treatment group who have evidence of resistance-associated substitutions will be analyzed at week 24. | Week 24 |
| Percentage of Participants With Development of Viral Drug Resistance to any Component of Study Intervention at Week 48 | Antiviral drug resistance is the reduced susceptibility of the virus to the study intervention. Participants with HIV-1 RNA ≥400 copies/mL will be included in the resistance analyses. Participants who have test results showing signs of viral resistance will also be included for analysis, irrespective of the viral load. Percentage of participants in each treatment group who have evidence of resistance-associated substitutions will be analyzed at week 48. | Week 48 |
| Percentage of Participants With Development of Viral Drug Resistance to any Component of Study Intervention at Week 96 | Antiviral drug resistance is the reduced susceptibility of the virus to the study intervention. Participants with HIV-1 RNA ≥400 copies/mL will be included in the resistance analyses. Participants who have test results showing signs of viral resistance will also be included for analysis, irrespective of the viral load. Percentage of participants in each treatment group who have evidence of resistance-associated substitutions will be analyzed at week 96. | Week 96 |
| Mills Clinical Research ( Site 4109) |
| West Hollywood |
| California |
| 90046 |
| United States |
| Georgetown University Medical Center ( Site 4106) | Washington D.C. | District of Columbia | 20007 | United States |
| Orlando Immunology Center ( Site 4103) | Orlando | Florida | 32803 | United States |
| Triple O Research Institute ( Site 4111) | West Palm Beach | Florida | 33407 | United States |
| Chatham County Health Department - Chatham CARE Center ( Site 4116) | Savannah | Georgia | 31401 | United States |
| KC CARE Health Center ( Site 4101) | Kansas City | Missouri | 64111 | United States |
| Regional Center for Infectious Diseases ( Site 4115) | Greensboro | North Carolina | 27401 | United States |
| Central Texas Clinical Research ( Site 4100) | Austin | Texas | 78705 | United States |
| Prism Health North Texas, Oak Cliff Health Center ( Site 4114) | Dallas | Texas | 75208 | United States |
| DCOL Center for Clinical Research ( Site 4112) | Longview | Texas | 75605 | United States |
| Momentum Clinical Research - Darlinghurst ( Site 4260) | Darlinghurst | New South Wales | 2010 | Australia |
| St. Vincent's Hospital ( Site 4263) | Darlinghurst | New South Wales | 2010 | Australia |
| Momentum Clinical Research Fortitude Valley ( Site 4261) | Fortitude Valley | Queensland | 4006 | Australia |
| The Alfred Hospital ( Site 4264) | Melbourne | Victoria | 3004 | Australia |
| Prahran Market Clinic ( Site 4262) | Prahran | Victoria | 3181 | Australia |
| Ponce Medical School Foundation Inc./CAIMED Center ( Site 4301) | Ponce | 00716 | Puerto Rico |
| Clinical Research Puerto Rico ( Site 4300) | San Juan | 00909 | Puerto Rico |
| HOPE Clinical Research ( Site 4303) | San Juan | 00909 | Puerto Rico |
| University Hospital Basel-Infectiology ( Site 4402) | Basel | Canton of Basel-City | 4031 | Switzerland |
| Inselspital Bern-Inselspital Infektiologie ( Site 4403) | Bern | Canton of Bern | 3010 | Switzerland |
| Hôpitaux Universitaires de Genève (HUG)-Infectious Disease Department ( Site 4404) | Geneva | Canton of Geneva | 1205 | Switzerland |
| Ospedale Regionale di Lugano, Sede Civico-Servizio Malattie Infettive ( Site 4405) | Lugano | Canton Ticino | 6900 | Switzerland |
| ID | Term |
|---|---|
| D000163 | Acquired Immunodeficiency Syndrome |
| D007239 | Infections |
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D015229 | Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C558823 | islatravir |
| C000723084 | ulonivirine |
| C000654125 | bictegravir, emtricitabine, tenofovir alafenamide, drug combination |
Not provided
Not provided
Not provided